Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alprostadil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 4/20 | 1.00 |
| ▸ | PTGER1 known ✓ | P34995 | 1/20 | 0.73 |
| ▸ | PTGIR | P43119 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprostadil SCHEMBL5436690 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL13399727 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL11854110 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL13199386 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23353047 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23353103 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23352620 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23352905 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL22425786 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL10198573 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020182077-A1 | USE OF GLI2 INHIBITOR AND METHOD FOR SCREENING COMPOUND INHIBITING GLI2 | 中国科学院动物研究所 | 2020-09-17 | — | — | WO | disclosed |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-10-02 | — | — | US | disclosed |
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2014-10-02 | — | — | US | disclosed |
| US-20090252685-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2009-10-08 | — | — | US | disclosed |
| US-20090252685-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS | PREMIER RESEARCH INTERNATIONAL, LLC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296191-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | PTGER2 69/4885PTGER1 20/4885PTGIR 399/4885 |
| US-20090252685-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PROSTAGLANDINS AND RELATED COMPOUNDS | PTGER1, HPGDS, PTGER2 | PTGER2 3/4885PTGER1 1/4885PTGIR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.